MedTrace Logo

A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.

NCT05571319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-06

No results posted yet for this study

Summary

Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus which frequently occur together. Data is emerging suggesting metabolic syndrome causes brain disease by contributing to blood vessel damage and inflammation. People living with HIV (PLWH) are at high risk and the investigators will perform a pilot study of the well-known type 2 diabetes drug metformin to treat this blood vessel damage and inflammation in PLWH.

Conditions

  • Metabolic Syndrome
  • HIV Seropositivity

Interventions

DRUG

Metformin Extended Release Oral Tablet

Glucophage XR 500 mg

Sponsors & Collaborators

  • University of Rochester

    collaborator OTHER

  • Fogarty International Center of the National Institute of Health

    collaborator NIH

  • University of Stellenbosch

    lead OTHER

Principal Investigators

  • Eric Decloedt, MBChB, PhD · University of Stellenbosch

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-11
Primary Completion
2025-03-24
Completion
2025-03-28

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05571319 on ClinicalTrials.gov